T Cell News and Research

Latest T Cell News and Research

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Injectable bone carries living stem cells

A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Cancer Research UK scientists have discovered how two genes can 'hijack' control of part of the body's defences against cancer, helping them grow and spread.

16 Jun 2010

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

16 Jun 2010

Study validates Grm1 protein as target for melanoma treatment

Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.

16 Jun 2010

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.

16 Jun 2010

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.

16 Jun 2010

Research investigates surgical outcomes of patients with NSCLC

Research published in the June edition of the Journal of Thoracic Oncology sought to investigate the time trends of surgical outcomes of patients with non-small cell lung cancer between 1979 and 2008. The incidence of lung cancer continues to rise; therefore, countermeasures to decrease death rates have become an important public health issue.

16 Jun 2010

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

Florida State University researcher explores role of key protein in cell division

A Florida State University researcher has identified the important role that a key protein plays in cell division, and that discovery could lead to a greater understanding of stem cells.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

The degradation of proteins and other macromolecules in cells is vital to survival. Disruption of this process can result in serious disease. The research group of Professor Thomas Jentsch (Leibniz Institute for Molecular Pharmacology, FMP/ Max Delbr-ck Center for Molecular Medicine, MDC, Berlin-Buch) has now succeeded in identifying an essential cellular process necessary for the transport and degradation of macromolecules in endosomes and lysosomes, respectively.

16 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

A new five-year, $1.8 million National Institutes of Health grant awarded to staff scientist Nikolaos Tapinos, M.D., Ph.D., of Geisinger's Sigfried and Janet Weis Center for Research will be used to study the role of nuclear ErbB3 protein during development of the nervous system and in response to nerve injury.

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

Robert H. Wurtz, PhD, a pioneer and leader in the field of neurophysiology, is the recipient of the 2010 Neuroscience Prize of The Peter and Patricia Gruber Foundation. His discoveries of how the brain processes visual information and controls eye movements laid the groundwork for subsequent research into the neurophysiology of visual cognition. This research has led scientists to a deeper understanding of how the brain is organized to produce behavior.

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

T Cell News and Research

Latest T Cell News and Research

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Injectable bone carries living stem cells

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

Study validates Grm1 protein as target for melanoma treatment

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Research investigates surgical outcomes of patients with NSCLC

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Florida State University researcher explores role of key protein in cell division

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

New combination appears to be effective against cancer stem cells in pancreatic cancer

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in